JP2012526769A5 - - Google Patents

Download PDF

Info

Publication number
JP2012526769A5
JP2012526769A5 JP2012510286A JP2012510286A JP2012526769A5 JP 2012526769 A5 JP2012526769 A5 JP 2012526769A5 JP 2012510286 A JP2012510286 A JP 2012510286A JP 2012510286 A JP2012510286 A JP 2012510286A JP 2012526769 A5 JP2012526769 A5 JP 2012526769A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
cycloalkyl
acceptable salt
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012510286A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012526769A (ja
JP5654572B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/056529 external-priority patent/WO2010130773A2/en
Publication of JP2012526769A publication Critical patent/JP2012526769A/ja
Publication of JP2012526769A5 publication Critical patent/JP2012526769A5/ja
Application granted granted Critical
Publication of JP5654572B2 publication Critical patent/JP5654572B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012510286A 2009-05-15 2010-05-12 アルドステロンシンターゼ阻害剤としてのベンズオキサゾロン誘導体 Expired - Fee Related JP5654572B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17868009P 2009-05-15 2009-05-15
US61/178,680 2009-05-15
US32722110P 2010-04-23 2010-04-23
US61/327,221 2010-04-23
PCT/EP2010/056529 WO2010130773A2 (en) 2009-05-15 2010-05-12 Benzoxazolone derivatives as aldosterone symthase inhibitors

Publications (3)

Publication Number Publication Date
JP2012526769A JP2012526769A (ja) 2012-11-01
JP2012526769A5 true JP2012526769A5 (enExample) 2013-06-20
JP5654572B2 JP5654572B2 (ja) 2015-01-14

Family

ID=42938295

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012510286A Expired - Fee Related JP5654572B2 (ja) 2009-05-15 2010-05-12 アルドステロンシンターゼ阻害剤としてのベンズオキサゾロン誘導体

Country Status (12)

Country Link
US (1) US8455522B2 (enExample)
EP (1) EP2430018B1 (enExample)
JP (1) JP5654572B2 (enExample)
KR (1) KR20120036850A (enExample)
CN (1) CN102459247B (enExample)
AU (1) AU2010247391A1 (enExample)
BR (1) BRPI1012852A2 (enExample)
CA (1) CA2761853A1 (enExample)
EA (1) EA201101621A1 (enExample)
ES (1) ES2430088T3 (enExample)
MX (1) MX2011012199A (enExample)
WO (1) WO2010130773A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5654572B2 (ja) 2009-05-15 2015-01-14 ノバルティス アーゲー アルドステロンシンターゼ阻害剤としてのベンズオキサゾロン誘導体
EP2430011A1 (en) 2009-05-15 2012-03-21 Novartis AG 5-pyridin-3-yl-1,3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or cyp11b1
BRPI1010600A2 (pt) 2009-05-15 2016-03-15 Novartis Ag aril piridina como inibidores de aldosterona sintase
ES2663351T3 (es) 2009-11-17 2018-04-12 Novartis Ag Derivados de aril-piridina como inhibidores de la aldosterona sintasa
RS59737B1 (sr) 2011-09-15 2020-02-28 Hoffmann La Roche Novi derivati dihidrohinolin-2-ona
EA037300B1 (ru) 2016-04-20 2021-03-05 Бристол-Маерс Сквибб Компани Замещенные бициклические гетероциклические соединения
SG11201903871TA (en) 2016-11-03 2019-05-30 Bristol Myers Squibb Co Substituted bicycle heterocyclic derivatives useful as romk channel inhibitors
WO2018165649A1 (en) 2017-03-10 2018-09-13 Embera Neurotherapeutics, Inc. Pharmaceutical compositions and uses thereof
CN110678463B (zh) 2017-06-01 2023-06-06 百时美施贵宝公司 经取代的含氮化合物
CN112599420B (zh) * 2020-12-28 2022-08-26 绵阳惠科光电科技有限公司 一种铟镓锌氧基多层结构薄膜晶体管的制备方法
CN121194968A (zh) * 2023-05-12 2025-12-23 江苏德源药业股份有限公司 含氮杂环类化合物及其应用
CN121712504A (zh) * 2023-07-27 2026-03-20 矿物疗法公司 用洛伦司他及两种或更多种降压药的组合治疗高血压的方法
CN118388379A (zh) * 2024-04-19 2024-07-26 大连理工大学 一种尼美舒利衍生物的有机全合成方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2951135A1 (de) 1979-12-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
DE3347565A1 (de) 1983-12-30 1985-07-11 Thomae Gmbh Dr K Neue phenylessigsaeurederivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPS61191681A (ja) * 1985-02-21 1986-08-26 Fujisawa Pharmaceut Co Ltd 4−イミダゾリン−2−オン誘導体
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
CN1029479C (zh) * 1989-11-08 1995-08-09 山之内制药株式会社 新型苯并噁嗪衍生物的制备方法
ATE164852T1 (de) 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
AU654331B2 (en) 1991-03-30 1994-11-03 Kissei Pharmaceutical Co. Ltd. Succinic acid compounds
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
WO1993000337A1 (de) 1991-06-21 1993-01-07 Dr. Karl Thomae Gmbh (s)(+)-2-äthoxy-4-[n-[1-(2-piperidino-phenyl)-3-methyl-1-butyl]aminocarbonylmethyl]-benzoesäure
EP0618803A4 (en) 1991-12-19 1995-03-22 Southwest Found Biomed Res POLYPEPTIDE INHIBITING PROTEIN TRANSFER TO CHOLESTERYL ESTERS, ANTIBODIES AGAINST SYNTHETIC POLYPEPTIDE AND ANTI-ATHEROSCLEROSIS PROPHYLACTIC AND THERAPEUTIC TREATMENTS.
US5508272A (en) 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
TW313568B (enExample) 1994-12-20 1997-08-21 Hoffmann La Roche
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
EP1175399B1 (en) 1999-04-23 2009-03-11 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk)
US6544974B2 (en) 1999-09-23 2003-04-08 G.D. Searle & Co. (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesteryl ester transfer protein activity
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2003086467A1 (en) 2002-04-08 2003-10-23 Smithkline Beecham Corporation Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US9259390B2 (en) 2003-08-13 2016-02-16 The University Of Houston System Parenteral and oral formulations of benzimidazoles
KR20060129023A (ko) * 2004-02-23 2006-12-14 다이닛본 스미토모 세이야꾸 가부시끼가이샤 신규한 헤테로환 화합물
EA200601785A1 (ru) 2004-03-26 2007-02-27 Эли Лилли Энд Компани Соединения и способы лечения дислипидемии
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
JP2008524246A (ja) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
CN101166722A (zh) 2005-04-29 2008-04-23 惠氏公司 制备3,3-二取代的羟吲哚和硫代羟吲哚的方法
PE20070220A1 (es) 2005-07-29 2007-03-19 Wyeth Corp Proceso para la sintesis de moduladores del receptor de progesterona
ES2348997T3 (es) * 2005-08-25 2010-12-21 Schering Corporation Compuestos de 3,4-dihidro-2h-benzo[1,4]oxazina y 3,4-dihidro-2h-benzo[1,4]tiazina como agonistas del adrenorreceptor alfa2c.
WO2008076336A2 (en) * 2006-12-18 2008-06-26 Novartis Ag Imidazoles as aldosterone synthase inhibitors
US20120121540A1 (en) 2007-08-10 2012-05-17 Franz Ulrich Schmitz Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections
DE102008022221A1 (de) 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
EP2430011A1 (en) 2009-05-15 2012-03-21 Novartis AG 5-pyridin-3-yl-1,3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or cyp11b1
BRPI1010600A2 (pt) 2009-05-15 2016-03-15 Novartis Ag aril piridina como inibidores de aldosterona sintase
JP5654572B2 (ja) 2009-05-15 2015-01-14 ノバルティス アーゲー アルドステロンシンターゼ阻害剤としてのベンズオキサゾロン誘導体

Similar Documents

Publication Publication Date Title
JP5066175B2 (ja) ヒスタミンh4受容体のモジュレーターとしてのベンゾイミダゾール−2−イルピリミジンおよびピラジン
JP2024010108A (ja) 心臓状態に対するピリミジンジオン化合物
JP5132673B2 (ja) ヒスタミンh4受容体のモジュレーターとしてのインドールおよびベンゾイミダゾール
CN110698415B (zh) 一种肌球蛋白抑制剂及其制备方法和用途
US9745282B2 (en) Indoline compounds as aldosterone synthase inhibitors
CA2679232A1 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
ES2802977T3 (es) Compuesto para la modulación inmunológica, uso del mismo y composición farmacéutica que lo comprende
JP5749410B2 (ja) ジヒドロピロロ[1,2−c]イミダゾリルアルドステロンシンターゼまたはアロマターゼ阻害薬の新たな形態および塩
BR112017000584B1 (pt) Compostos heteroarila, composição farmacêutica e seus usos como inibidores da aldosterona sintase
WO2019244000A1 (en) Phenyl and pyridinyl substituted imidazoles as modulators of roryt
JP2017500321A5 (enExample)
JP2011526911A (ja) ベンゾイミダゾール−2−イルピリミジン誘導体を製造する方法
PT1487424E (pt) 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-il-amino)fenil]-benzamida para o tratamento doenças mediadas por ang ii
JP4950170B2 (ja) 新規フェニルアセテート誘導体またはその薬学的に許容可能な塩、その製造方法及びそれを有効成分として含むt−型カルシウムイオンチャンネルの活性によって誘発される疾患の予防または治療用組成物
JP5859115B2 (ja) 1,4−ジヒドロピリジン−3,5−ジカルボキシラート誘導体、その調製方法及びその使用
US20150306091A1 (en) Aldosterone synthase inhibitors
WO2009088063A1 (ja) 医薬組成物、医薬組成物製造のための2-イミノピロリジン誘導体の使用および心疾患の治療用または改善用キット
JP2012505225A5 (enExample)
KR20240130685A (ko) 화합물, 안지오텐신 ii 타입 1 수용체 길항제 및 의약 조성물
TW201000097A (en) Medicament for the prophylaxis or treament of hypertension
US9522141B2 (en) Indazole compounds as aldosterone synthase inhibitors
NZ766570A (en) Pyrimidinones as factor xia inhibitors
NZ766570B2 (en) Pyrimidinones as factor xia inhibitors
JP2012526773A5 (enExample)
NZ731416B2 (en) Pyrimidinones as factor xia inhibitors